Bioconjugates: The Adaptable Challenge - Conjugation of a biologic to a carrier molecule can solve problems in solubility and stability, but introduces its own set of challenges. - BioPharm


Bioconjugates: The Adaptable Challenge
Conjugation of a biologic to a carrier molecule can solve problems in solubility and stability, but introduces its own set of challenges.

BioPharm International
Volume 26, Issue 1, pp. 34-38


Table I: Table of PEGylated pharmaceuticals (brand name) currently on the market in reverse chronology by FDA approval year with sponor and indication.
ADAGEN (PEG-bovine adenosine deaminase) manufactured by Enzon Pharmaceuticals was the first PEGylated protein approved by FDA in March 1990. It is used to treat X-linked severe combined immunogenicity syndrome, as an alternative to bone marrow transplantation and enzyme replacement by gene therapy. Since the introduction of ADAGEN, a large number of PEGylated protein and peptide pharmaceuticals have followed, and many others are under clinical trial or under development stages (see Tables I and II). On Mar. 27, 2012, FDA announced the approval of the first PEGylated peptide, Peginesatide, for the treatment of anemia associated with chronic kidney disease.

Table II: Peptide Bioconjugates currently marketed or in clinical trials. Data source: reference 4.
Although PEG has been successfully used in increasing the half-life of proteins and peptides, there are some challenges and concerns, in particular, risk associated with chronic administration of high dose PEGylated peptides (3). Although, PEGs can be filtered through the kidneys over time, high doses of PEGylated peptides and proteins can cause accumulation of the bioconjugate at the target organ and at other organs in the body. The clearance rate of peptides and proteins is lower when they are conjugated with a large steric moiety such as PEG. At high doses of the PEG conjugate, the metabolic system can be overloaded, resulting in poor clearance of the peptide or protein. Ultimately, any observed toxicity due to high doses of the PEG conjugate is dependent on the design of the conjugate (i.e., the location of PEG on the molecule in relation to the active part of the peptide), the target organ, the conjugate's mechanism of action, and the toxicological action of the peptide or protein on nearby organs.

PEGylation of peptides has a number of analytical hurdles that may become more of a concern for regulatory authorities. The economic cost of PEG derivatives and their availability are also of concern. The yield of PEGylation is typically in the range of 45% to 60% and therefore, for every unit of bioconjugate, twice as much PEG would have to be purchased. A contract manufacturer views the purchase of PEG in similar terms to the purchase of other raw materials such as amino acids. Amino acids cost approximately $1 per gram at large scale whereas PEG can cost in the range of $200–$500 per gram. Conversely, the innovator of a PEGylated peptide may view a fair cost comparison to be between the peptide and PEG, in which case the PEG may be lower in cost. As the scale of a peptide project increases from hundreds of grams to several kilograms, the cost of PEG in the manufacturing of PEGylated peptides will probably become the main driving cost of manufacture. Ultimately, the deciding factor on the economies of using a PEG bioconjugate would be dependent on the dosage of the final drug.

Many PEGs are unique and are only available from one PEG vendor. This single sourcing is of concern because as projects mature and commercialize, it is important to have alternative sources of raw materials to mitigate risk. The single source of PEG also raises the question of how generic companies can enter the market with PEGylated biosimilars. From the innovators point of view, the use of a PEG with a proprietary linker may provide exclusive patent protection even though royalties may be required by the PEG raw-material vendor. From a risk-mitigation stand point, a single vendor source would have to provide some sort of contingency plan in transferring their proprietary linker technology to a third party in the event the operations of the single-vendor source shut down for an extended period of time.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here